Flecainide

Generic Name: Flecainide

Brand Names: Tambocor

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀F_₆N_₂O_₃

CAS Number: 54143-55-4

Unique Ingredient Identifier: K94FTS1806

Background: Flecainide is a Class I anti-arrhythmic agent like encainide and propafenone. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.
...

Indication: In New Zealand and America, flecainide is indicated to prevent supraventricular arrhythmias and ventricular arrhythmias. In the United States, it is also indicated to prevent paroxysmal atrial fibrillation and flutter.

Associated Conditions: Atrial Fibrillation, Ventricular Tachycardia (VT), Severe Atrioventricular nodal reentrant tachycardia, Severe Paroxysmal atrial fibrillation, Severe Paroxysmal supraventricular tachycardia, Severe Supraventricular Tachycardias, Severe Sustained ventricular tachycardia, Severe ventricular arrhythmias

Associated Therapies: -

Clinical Trials

Acupuncture in Persistent Atrial Fibrillation

Not Applicable

Conditions: Persistent Atrial Fibrillation

Interventions: Procedure: Active Acupuncture
Procedure: Sham acupuncture
Drug: flecainide

First Posted Date: 2014-04-10

Last Posted Date: 2014-04-10

Lead Sponsor: Kyunghee University Medical Center

Target Recruit Count: 80

Registration Number: NCT02110537

Locations: 🇰🇷
Kyung Hee University Medical Center, Seoul, Dongdaemun-gu, Korea, Republic of

Vernakalant Versus Flecainide: Atrial Contractility

Phase 4

Conditions: Atrial Fibrillation

Interventions: Drug: Flecainide
Drug: Vernakalant

First Posted Date: 2012-07-20

Last Posted Date: 2012-07-20

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 70

Registration Number: NCT01646281

Locations: 🇳🇱
Maastricht University Hospital, Maastricht, Netherlands

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

Not Applicable

Completed

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia

Interventions: Drug: Flecainide Acetate
Drug: Placebo
Drug: Beta blocker

First Posted Date: 2010-05-05

Last Posted Date: 2017-06-14

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 14

Registration Number: NCT01117454

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

and more 7 locations

Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias

Phase 4

Completed

Conditions: Atrial Fibrillation
Tachycardia, Ventricular
Brugada Syndrome

Interventions: Drug: procainamide
Drug: ajmaline
Drug: flecainide

First Posted Date: 2008-06-20

Last Posted Date: 2010-12-15

Lead Sponsor: Hospital Clinic of Barcelona

Target Recruit Count: 123

Registration Number: NCT00702117

Locations: 🇪🇸
Hospital Puerta de Hierro, Madrid, Spain
🇪🇸
Hospital Donostia, Donostia, Guipuzcoa, Spain
🇪🇸
Hospital La Fe, Valencia, Spain

and more 1 locations

Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.

Phase 4

Terminated

Conditions: Atrial Fibrillation

First Posted Date: 2006-12-07

Last Posted Date: 2022-02-07

Lead Sponsor: MEDA Pharma GmbH & Co. KG

Target Recruit Count: 256

Registration Number: NCT00408473

Locations: 🇫🇷
Patrick KOHAN, 18 rue de la Commanderie, Nancy, France
🇧🇬
Department of Cardiology, MHAT Burgas AD, 73 Stefan Stambolov blvd, Burgas, Bulgaria
🇧🇪
Hôpital St.-Joseph, Rue de la Duchère 6, Gilly, Belgium

and more 44 locations

High Intensity Focused Ultrasound (HIFU) Ablation System Study

Phase 3

Suspended

Conditions: Atrial Fibrillation

Interventions: Drug: propafenone
Device: Pulmonary vein ablation
Drug: flecainide
Drug: dofetilide
Drug: sotolol
Drug: Amiodarone

First Posted Date: 2006-10-25

Last Posted Date: 2008-06-17

Lead Sponsor: ProRhythm, Inc.

Target Recruit Count: 240

Registration Number: NCT00392106

Locations: 🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States

and more 18 locations

Flecainide-Short Long Study (Flec-SL)

Not Applicable

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Flecainide

First Posted Date: 2005-09-22

Last Posted Date: 2012-09-11

Lead Sponsor: Atrial Fibrillation Network

Target Recruit Count: 760

Registration Number: NCT00215774

Flecainide in Treating Patients With Chronic Neuropathic Pain

Phase 2

Completed

Conditions: Pain

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 20

Registration Number: NCT00002996

Locations: 🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States
🇺🇸
CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
🇺🇸
CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States

and more 3 locations

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

Phase 3

Completed

Conditions: Atrial Fibrillation
Cardiovascular Diseases
Arrhythmia
Heart Diseases

First Posted Date: 1999-10-28

Last Posted Date: 2016-03-25

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000556

Cardiac Arrhythmia Pilot Study (CAPS)

Phase 2

Completed

Conditions: Arrhythmia
Cardiovascular Diseases
Heart Diseases
Ventricular Arrhythmia

First Posted Date: 1999-10-28

Last Posted Date: 2012-04-27

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000504

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy